Remedy Plan developed a pioneering approach to drug development against essential targets, shifting the therapeutic landscape for multiple diseases. Our clinical candidate, RPT1G, is a hyperbolic inhibitor that targets NAMPT, an essential enzyme that is critical for healthy cell biology but dysregulated in dozens of diseases, including cancer.
Unlocking the opportunity of NAMPT inhibition
Remedy Plan developed a revolutionary medical treatment that targets an essential enzyme—NAMPT—which is critical for healthy cell biology, but becomes dysregulated in dozens of diseases, including cancer. This approach could shift the therapeutic landscape in diseases where essential targets play a key role in disease.
Unlocking the opportunity of NAMPT inhibition
NAMPT: Core regulator of human biology
NAMPT is an essential enzyme that controls how cells use energy. NAMPT dysregulation is present in more than 20 diseases and plays a critical role in oncology and systemic disorders. Targeting NAMPT unlocks a universal lever for human health. Its ubiquity in critical biological pathways presents a unique opportunity to deliver a transformative clinical breakthrough.
The central challenge in targeting NAMPT is achieving meaningful disease control while preserving the essential metabolic function of healthy cells. Disruption of normal cellular metabolism has historically led to severe toxicities. Despite extensive efforts across academia and leading pharmaceutical companies, this balance had remained out of reach.
This all changes with Remedy Plan's pioneering approach.
This all changes with
Remedy Plan's pioneering approach.
Developing the first hyperbolic inhibitors
Remedy Plan is the first to solve the key challenge of inhibiting NAMPT activity by turning activity down, not off—an approach called hyperbolic inhibition. This solved NAMPT’s on-target toxicity profile, something that the industry grappled with for decades.
